Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8825927 | 0.95 | MGLL (0.38) | MGLL | |
| SCHEMBL12912977 | 0.95 | MGLL (0.38) | MGLL | |
| SCHEMBL13835372 | 0.95 | MGLL (0.38) | MGLL | |
| SCHEMBL17603026 | 0.95 | MGLL (0.38) | MGLL | |
| SCHEMBL514846 | 0.94 | MGLL (0.33) | MGLL | |
| SCHEMBL19593693 | 0.89 | MGLL (0.40) | MGLL | |
| SCHEMBL9501105 | 0.89 | MGLL (0.40) | MGLL | |
| SCHEMBL20853812 | 0.89 | — | — | |
| SCHEMBL19474824 | 0.89 | MGLL (0.40) | MGLL | |
| SCHEMBL513991 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57145819-A | — | — | None | — | — | JP | disclosed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-3133058-B1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10266476-B2 | (Meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-10065916-B2 | Method for producing (meth)acrylate | TOAGOSEI CO., LTD (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20180237629-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180187026-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20160229962-A1 | SILICONE CHAIN EXTENDER | DANMARKS TEKNISKE UNIVERSITET (DK) | 2016-08-11 | — | — | US | disclosed |
| EP-3052508-A1 | SILICONE CHAIN EXTENDER | Danmarks Tekniske Universitet (DK) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015043792-A1 | SILICONE CHAIN EXTENDER | DANMARKS TEKNISKE UNIVERSITET (DK) | 2015-04-02 | — | — | WO | disclosed |
| US-8506913-B2 | Acidic gas absorbent, acidic gas removal device, and acidic gas removal method | KABUSHIKI KAISHA TOSHIBA (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2013082751-A1 | PHOSPHATE TRANSPORT INHIBITORS I | LEO PHARMA A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013082756-A1 | PHOSPHATE TRANSPORT INHIBITORS II | LEO PHARMA A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
| EP-2554243-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | Kabushiki Kaisha Toshiba (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120294785-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-11-22 | — | — | US | disclosed |
| JP-S57145819-A | INTRODUCING METHOD OF THIOCARBOXYL OR SELENOCARBOXYL GROUP | MITSUBISHI CHEM IND LTD | 1982-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229962-A1 | SILICONE CHAIN EXTENDER | MSN, SMCHD1, MMS19 | MGLL 719/4885 |
| US-10065916-B2 | Method for producing (meth)acrylate | MMAB, ADH5, ADH1A | MGLL 646/4885 |
| US-20180187026-A1 | CURABLE COMPOSITION | AZI2, KAT2A, KAT2B | MGLL 1219/4885 |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | MMAB, AMD1, ADH5 | MGLL 240/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | MGLL 42/4885 |
| US-10266476-B2 | (Meth)acrylate manufacturing method | MMAB, PAM, MAT2B | MGLL 670/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | MGLL 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.